Anti-CD44 monoclonal antibody IM7

Drug Profile

Anti-CD44 monoclonal antibody IM7

Alternative Names: Anti-CD44 monoclonal antibody IM7.8.1; IM7; IM7.8.1

Latest Information Update: 31 Oct 2002

Price : $50

At a glance

  • Originator Rush-Presbyterian-St. Lukes Medical Center
  • Developer Hebrew University of Jerusalem; Imperial College of Science, Technology and Medicine; Rush-Presbyterian-St. Lukes Medical Center; Western General Hospital
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action CD44 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 09 Nov 2000 No-Development-Reported for Multiple sclerosis in United Kingdom (Unknown route)
  • 09 Nov 2000 No-Development-Reported for Multiple sclerosis in USA (Unknown route)
  • 09 Nov 2000 Preclinical development for Rheumatoid arthritis in United Kingdom (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top